Femtech Startup Funding 2025-2026

What are all the funding deals in the femtech market from July 2025 to June 2026?

The table below lists every disclosed equity or equity-like round raised by pure-play femtech companies between July 2025 and June 2026. We define the femtech market as technology-enabled products and services that address women’s reproductive and other female-specific health needs.

Each row shows the company, what it does, its category, the deal date, the funding stage, the round size, the region, the main investors when available in the dataset, and the announcement source. For a wider view of how femtech fits inside women’s health innovation, we cover it in our Femtech market report.

How active has fundraising been in the femtech market?

As of June 2026, fundraising in the femtech market has been active but uneven. Over the past 12 months, companies raised 23 disclosed equity or equity-like rounds and $412.605M combined.

That works out to an average of 1.92 disclosed deals per month. The median monthly deal count was 1.5, which shows that activity was present but not evenly distributed.

September 2025 was the standout month in the femtech market. It produced 8 deals and $205.31M, meaning one month accounted for almost half of the disclosed capital in the dataset.

There were also quiet months. October 2025, December 2025, and the first eight days of June 2026 had no qualifying disclosed rounds in the core sample.

If you want to go deeper on this activity pattern, see our market report covering femtech fundraising.

How concentrated has fundraising been in the femtech market?

As of June 2026, fundraising in the femtech market has been highly concentrated. Over the past 12 months, the top deal alone accounted for 24.24% of all disclosed capital.

The top 3 deals represented 51.87% of total capital, and the top 5 represented 74.65%. That means most capital came from a small number of companies, not from a broad funding wave.

The top 10 deals represented 91.37% of all disclosed capital. This is the clearest sign that headline market totals should be interpreted through concentration first.

The median round was $6M, while the average round was $17.939M. That gap confirms that a few large rounds pulled the market average far above the typical financing.

How much of the femtech funding signal is driven by outliers?

As of June 2026, a large part of the femtech funding signal is driven by outliers. Over the past 12 months, 4 deals were in the $50M+ size bucket, including Midi Health, Mercy BioAnalytics, Diana Health, and Conceivable Life Sciences.

Only 3 deals were strictly above $50M, equal to 13.04% of all deals. Midi Health’s $100M Series D is counted in the $50M+ size bucket, but not as a deal over $100M.

Rounds above $50M set the market narrative, even though most companies raised much smaller checks. Excluding rounds above $50M leaves $198.605M, less than half of the original $412.605M total.

This is why the femtech market should not be described only by aggregate capital raised. The better reading is that a few clinically validated or platform-scale companies captured most of the dollars.

Is the femtech market broad with many targets, or narrow with few fundable companies?

As of June 2026, the femtech market is broad in founder formation but narrow in large-scale funding. Over the past 12 months, 23 unique companies raised 23 disclosed rounds, so the dataset does not depend on repeat raises by the same company.

The breadth is visible across categories. The dataset includes fertility care, pregnancy care, menstrual health, hormonal health, and women’s primary care.

But capital did not spread evenly across those categories. Women’s Primary Care, Hormonal Health Platforms, and Fertility Care Platforms together captured 94.01% of disclosed capital.

Pelvic Care Devices had no counted disclosed equity rounds in the core dataset. That absence does not prove there is no need, but it does show that visible investor attention was elsewhere during the period.

Is femtech mostly an early-stage formation market or a late-stage scaling market?

As of June 2026, the femtech market is early-stage by deal count but late-stage by dollars. Over the past 12 months, Seed and Series A rounds represented 18 of 23 deals, or 78.26% of all disclosed activity.

Seed rounds alone accounted for 12 deals, equal to 52.17% of total deal count. But those Seed rounds raised only $38.305M, or 9.28% of disclosed capital.

Late-stage rounds told the opposite story. Series B, Series C, Series D+, and Growth Equity represented 63.47% of all capital, even though they were a much smaller share of deal count.

This means the femtech market still has many experiments, but most money flows to companies with clinical, commercial, regulatory, or care-delivery validation. We cover the stage split in more detail in our deeper analysis of the femtech market.

Which categories attract the most investor attention in femtech?

As of June 2026, Women’s Primary Care attracted the most investor attention in the femtech market. Over the past 12 months, it led both by deal count and by capital, with 7 deals and $153.5M raised.

Hormonal Health Platforms ranked second by capital, with $117.61M across 6 deals. Fertility Care Platforms followed closely with $116.825M across 5 deals.

Menstrual Health Tools had 3 deals but only $15.1M in total capital. Pregnancy Care Solutions had 2 deals and $9.57M, which shows that activity existed but check sizes were smaller.

The investor attention pattern is clear. Categories tied to integrated care, menopause, fertility infrastructure, diagnostics, and women-specific clinical workflows attracted larger funding pools than lighter consumer product categories.

Which categories attract disproportionately large checks in the femtech market?

As of June 2026, Fertility Care Platforms attracted the most disproportionately large checks in the femtech market. Over the past 12 months, the category had 21.74% of deals but 28.31% of capital, giving it a capital-share-to-deal-share ratio of 1.30.

Women’s Primary Care also over-indexed. It had 30.43% of deals and 37.20% of capital, producing a ratio of 1.22.

Hormonal Health Platforms sat slightly above parity, with 26.09% of deals and 28.50% of capital. That reflects the pull of menopause and hormonal-care models, especially Midi Health’s $100M Series D.

Pregnancy Care Solutions and Menstrual Health Tools under-indexed on check size. Their ratios were 0.27 and 0.28, which means these categories received visible backing but not the largest institutional checks.

Which geographies matter most for fundraising in the femtech market?

As of June 2026, North America matters most for fundraising in the femtech market. Over the past 12 months, the region captured $383.025M, or 92.83% of all disclosed capital.

North America also led by deal count, with 13 of 23 disclosed rounds. Its average deal size was $29.463M, and its median deal size was $20M.

Europe was second by deal count, with 5 deals, but it captured only $17.28M. That equals 4.19% of disclosed capital, showing a much thinner growth-capital layer.

Asia-Pacific and the Middle East appeared in the dataset, but their rounds were smaller. Asia-Pacific raised $5.1M across 3 deals, while the Middle East raised $7.2M across 2 deals.

For more context on the regional split, see our full market deck on femtech.

Is the femtech opportunity set broad or concentrated in one hub?

As of June 2026, the femtech opportunity set is global by company formation but concentrated in North America by capital. Over the past 12 months, four regions produced qualifying deals, but one region captured nearly all the money.

North America had 56.52% of deals and 92.83% of capital. That is a major funding-scale asymmetry, not just a difference in deal count.

Europe had 21.74% of deals but only 4.19% of capital. The European femtech market appeared fundable at seed and early levels, but it did not show many large growth financings in this dataset.

Latin America and Africa had no qualifying disclosed equity rounds in the core dataset. This should not be read as absence of need, but rather as absence of visible venture funding under the tracker’s filters.

Is femtech a market of small experiments or scaled financings?

As of June 2026, the femtech market is mostly a market of small experiments by count and scaled financings by dollars. Over the past 12 months, 11 of the 23 disclosed rounds were under $5M.

Another 5 deals were between $5M and $20M, while 3 deals were between $20M and $50M. Only 4 deals were in the $50M+ bucket.

The distribution explains why the average and median round sizes diverge. The median round was $6M, but the average was $17.939M because a few large clinical or platform rounds lifted the mean.

The femtech market therefore has a bifurcated structure. Most companies are still forming or proving early models, while a small group has reached the evidence threshold for large institutional capital.

Who are the investors that appear the most in femtech fundraising?

As of June 2026, only seven investors appeared in more than one disclosed femtech round. Over the past 12 months, repeat investor activity was visible, but not broad enough to suggest a crowded specialist investor base.

Advance Venture Partners appeared in Conceivable Life Sciences and Midi Health. ARTIS Ventures appeared in Conceivable Life Sciences and ONTO Health.

Alumni Ventures appeared in Lōvu Health and Emm, while Emmeline Ventures appeared in Lōvu Health and Osteoboost Health. Impact Shakers Ventures appeared in Solence and Evela Health.

Overwater Ventures appeared in Gameto and BeSound, and Portfolia appeared in Gameto and Osteoboost Health. These repeat names suggest that specialist or thesis-driven capital remains important in the femtech market.

One caveat matters: round announcements rarely disclose individual check sizes. So investor recurrence should be read as participation frequency, not as a precise ranking of dollars committed.

What kinds of femtech companies raised the largest rounds?

As of June 2026, the largest femtech rounds went to companies tied to clinical, reimbursable, regulated, or infrastructure-like care. Over the past 12 months, the biggest checks did not go to lightweight wellness or generic consumer apps.

Midi Health, Mercy BioAnalytics, Diana Health, Conceivable Life Sciences, and Gameto each raised large rounds because they addressed concrete care bottlenecks. Those bottlenecks included menopause care access, ovarian cancer detection, hospital-partnered women’s care, IVF lab automation, and reproductive cell therapy.

This is an important reading rule for the femtech market. Investors rewarded companies that connected women-specific biology to clinical workflows, provider shortages, diagnostics, or fertility infrastructure.

AI appeared in many company descriptions, but AI alone did not explain large funding. The larger AI-adjacent rounds were attached to specific care pathways, not generic wellness use cases.

What does the femtech funding data say about market maturity?

As of June 2026, the femtech funding data suggests a market with growing credibility but uneven maturity. Over the past 12 months, there were enough Seed rounds to show continued founder formation, but most capital still went to validated companies.

The credibility standard appears to be rising. Larger rounds often referenced FDA clearance, clinical trials, hospital partnerships, physician-led care, diagnostics, or infrastructure-level care delivery.

The market is also moving beyond narrow reproductive-health framing. The dataset includes ovarian cancer, breast cancer, menopause-linked bone density, menstrual-fluid diagnostics, PCOS, IVF automation, and women’s primary care.

The best interpretation is not that every femtech category is scaling equally. It is that the femtech market is expanding from life-stage apps into biology-specific clinical infrastructure. You can find a deeper analysis of these maturity signals in our femtech market report.

What is the main takeaway from femtech funding between July 2025 and June 2026?

As of June 2026, the main takeaway is that the femtech market is validated but not evenly funded. Over the past 12 months, 23 companies raised $412.605M, but the top 10 deals captured 91.37% of that capital.

The strongest funding signal came from clinical and infrastructure-heavy models. Investors backed care delivery, diagnostics, IVF infrastructure, reproductive therapies, menopause care, and women-specific clinical platforms.

Smaller categories still matter, but they were not the main dollar drivers. Menstrual Health Tools and Pregnancy Care Solutions had visible activity, yet together represented only 5.98% of disclosed capital.

The reusable conclusion is simple. Femtech companies that turn female-specific biology into a reimbursable or clinically anchored workflow raised larger rounds than companies built mainly around consumer branding.

Who is the author of this content?

NEW MARKET PITCH TEAM

We track new markets so founders and investors can move faster

We build living "market pitch" documents for emerging markets: AI, synthetic biology, new proteins, and more. Instead of outdated PDFs or hallucinated LLM answers, our clients get a clean, visual, always-updated view of what's really happening: key players, deals, regulations, and signals that matter. Learn more about us.